HOLD PM: Mid-range consolidation with pre-committed ATR-adjacent triggers; collect dividend carry, don't front-load exposure
HOLD PM at $191.71. The 8/14 lesson forecloses Buy/Overweight adds within ~5–6 weeks of Q3 binary earnings at 20.9x forward P/E. The 8/21 lesson forecloses Underweight with intact rising 200 SMA and $10.7B FCF covering dividend 1.24x. The 9/14 reflection forecloses opportunistic trims at current levels. Execute the Neutral Analyst's ATR-adjacent trigger architecture: add ¼ on $189–$190 weakness pullback, add second tranche on $194.50 volume-confirmed breakout, trim 15% on $195–$196 if $200 fails or on confirmed >$200 breakout. Collect the 3.03% covered dividend as carry through the Q3 earnings gate.
| Position | Action |
|---|---|
| Current price $191.71 (mid-range within $182–$196 consolidation) | Do NOT add; maintain current position weight; collect 3.03% covered dividend as carry |
| Price pulls back to $189–$190 on declining volume | ADD ¼ position; stop placement below $187 |
| Confirmed close >$194.50 on >5M volume with positive MACD histogram and RSI >55 | ADD full second tranche (0.5x normal notional); participate in breakout |
| Confirmed close >$200 on volume >5M with positive MACD histogram and RSI >55 | TRIM 15% — momentum-confirmed breakout capture |
| Price at $195–$196 if fails to break $200 | TRIM 15% opportunistically |
| Confirmed weekly close <$182 on volume >5M with MACD bearish cross | TRIM additional 15% — Tier 2 trim |
| Any new PM position initiation | Position sizing cap: 2–3% maximum |
| Existing position | Trail stop to $187.00 (just below 50 SMA buffer) |
| 200 SMA break with volume | Hard stop at $170 for capital preservation |
PM is a defensive compounder in structural transformation from combustibles to high-margin smoke-free products, with best-in-class 40% operating margins, $10B+ annual FCF, and multi-year ZYN growth catalysts positioning it as a quality holding in a higher-for-longer rate regime.
| Indicator | Value | Signal |
|---|---|---|
| Close (2026-09-16) | 191.71 | neutral |
| 10 EMA | 190.46 | bullish |
| 50 SMA | 189.03 | bullish |
| 200 SMA | 173.94 | bullish |
| RSI (14) | 53.95 | bullish |
| MACD | 0.82 | bullish |
| MACD Signal | 0.27 | bullish |
| MACD Histogram | +0.55 | bullish |
| Bollinger Upper Band | 196.58 | neutral |
| Bollinger Lower Band | 182.88 | bullish |
| Bollinger Mid (20 SMA) | 189.73 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price pulls back to $189–$190 on declining volume
Then: ADD ¼ position with stop below $187
PM generates world-class margins that justify premium valuation, with FCF of $10B+ and deleveraging already underway
EV: +5-10% near-term on breakout above $196.58 upper Bollinger Band, structural uptrend intact · concedes: Upper Bollinger Band at $196.58 offers only ~2.5% near-term upside from current levels; Optimal entry for new capital is pullback to $189-$190 rather than current price; Bear arguments on premium valuation and Zyn concentration have surface-level merit requiring active monitoring
PM at $191.71 is a bull trap where the easy money has been made, with premium valuation (26.3x P/E, 20.9x forward, 2.34 PEG), late-cycle technical signals (MACD cross after a 5.5% run), and ZYN concentration risk creating asymmetric downside risk that outweighs the limited upside from current levels.
EV: $175-$180 (8-10% downside from $191.71) · concedes: 3.03% dividend yield provides some downside cushion; FDA authorization for ZYN represents current market access; $0.24 FX guidance raise was a real benefit for 1-2 quarters; MACD crossing bullish above zero is technically constructive; Bollinger Band squeeze could resolve with upside breakout; Some institutional accumulation evident in price action; ZYN's 40%+ YoY growth is real and significant
→ vs conservative: Treating the $200 rejection as a stop sign and distribution pattern is wrong — it's base-building consolidation, not a topping pattern
→ vs conservative: Higher-for-longer Fed with low recession odds is a buy signal for quality compounders like PM with pricing power and defensive beta, not a headwind
→ vs neutral: 20.9x P/E is not stretched — PM is no longer a typical tobacco comp but a 40% operating margin, FDA-cleared smoke-free transformation story requiring a different comp set than legacy cigarette makers
→ vs neutral: The 80% FCF payout ratio concern is lazy analysis — OCF was $12.23B, dividends were $8.62B (70% of OCF), and there's $4.87B cash plus $18B+ EBITDA cushion with no fragility in the balance sheet
→ vs conservative: The asymmetric risk argument (bear needs one thing to break, bull needs eight) misreads the setup — the bull needs only continued execution on an already FDA-cleared, ramping transformation with multiple confirming datapoints
| bullish |
| ATR (14) | 4.66 | neutral |
Support: 196.58 · 200.17 · 191.71 · 190.46 · 189.73 · 189.03 · 182.88 · 182.53 | Resistance: 182.88 · 182.53 · 189.03 · 189.73 · 190.46 · 191.71 · 196.58 · 200.17
PM is in a mature, structurally bullish long-term uptrend that began after the October 2025 low (~$140) and is now consolidating near all-time highs in the $182–$196 zone. Current close is $191.71, sitting at ~38% within the Bollinger Band range (UB: 196.58, LB: 182.88). The 200 SMA is rising at 173.94 (+7.6% since May 2026), with price 10.2% above this level. RSI recovered from oversold territory (40.57 on Sep 4) to 53.95 with positive divergence, while MACD generated a fresh bullish crossover above zero on Sep 14. ATR has contracted ~22% since late July (5.94 to 4.66), signaling compressed volatility and coiled energy for potential expansion. The recommendation is HOLD: existing holders should trail stops to $187.00; new capital can stage entry with ½ position at ~$191.50 and add on breakout above $194.50 or pullback to $189–$190. Invalidation below $186.00.
Market Cap
$298.8 B
Share Price (Implied)
~$191.7
P/E (TTM)
26.3x
Forward P/E
20.9x
PEG Ratio
2.34
Price/Book
-34.8x
Dividend Yield
3.03%
Beta
0.39
52-Week High
$207.76
52-Week Low
$142.11
50-Day Avg
$188.95
200-Day Avg
$175.45
TTM Revenue
$42.55 B
TTM Net Income
$10.84 B
Diluted EPS (TTM)
$7.28
Diluted Shares
1.557 B
Net Revenue 2024
$37.88 B
Net Revenue 2025
$40.65 B
Revenue CAGR (4yr)
~8.4%
Gross Margin
67.5%
Operating Margin
40.0%
Net Margin
25.6%
ROA
14.6%
EBITDA 2025
$17.46 B
EBITDA (TTM)
$18.02 B
EBITDA Margin
42.3%
Operating CF 2025
$12.23 B
Free Cash Flow (TTM)
$9.71 B
Free Cash Flow 2024
$10.77 B
Free Cash Flow 2025
$10.66 B
CapEx 2025
$1.57 B
Dividends Paid 2025
$8.62 B
D&A
~$2.0 B
Total Debt 2025
$48.84 B
Net Debt 2025
$43.96 B
Cash 2025
$4.87 B
Net Debt/EBITDA
2.52x
Net Debt/EBITDA 2024
2.63x
Current Ratio 2025
0.96x
Stockholders' Equity
($9.99 B)
Total Assets 2025
$69.19 B
Total Liabilities 2025
$77.21 B
Interest Coverage
~10x
FCF Payout Ratio
~80%
EPS CAGR (4yr normalized)
~7.7%
Forward EPS Forecast
$9.17
2026E Revenue
$43–45 B
ZYN Shipment Growth 2024
>40% YoY
Smoke-free Revenue Target
2/3
Cigarette Volume Decline
~2–4% annually
FX Exposure
~70%
Strengths
Concerns
Philip Morris International is a high-quality defensive compounder trading near its 52-week high with a 26.3x P/E valuation premium justified by world-class profitability (67.5% gross margin, 40% operating margin) and superior cash generation ($9.71B TTM FCF). The company's secular transformation into smoke-free products (ZYN, IQOS) is accelerating, with management targeting 2/3 of revenue from reduced-risk products by 2030 versus ~40% currently, supported by >40% ZYN shipment growth. Despite substantial leverage ($43.96B net debt, 2.52x Net Debt/EBITDA), robust interest coverage (~10x) and an 80% FCF payout ratio support the 3.03% dividend yield and deleveraging trajectory, though the negative equity balance ($9.99B) and premium valuation temper near-term upside.
Macro: Hawkish Fed surprise: central bank hiked rates with Dow sinking 600 points and bond yields rising post-hike. Dimon (JPM) voiced inflation concerns ('not clear we've slayed inflation'). Polymarket odds: 95% probability of NO Fed cuts in 2026 (+1.9pp w/w); 12% chance of US recession by end-2026 (+4pp w/w). 10Y Treasury sat below 5% ahead of decision then rose post-hike. Broad consumer defensives sold off into Fed decision. Dollar strength headwind for EM-revenue multinationals partially offset by PM's FX guidance raise of ~$0.24.